Melanoma

News and reporting on melanoma.

Sep 1, 2022

SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay

Aug 26, 2022

Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label
Premium

Jul 27, 2022

BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles
Premium

Jul 22, 2022

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

Jul 21, 2022

MD Anderson, Obsidian Therapeutics to Launch First-In-Human Trial of Engineered TILs for Melanoma

Jul 21, 2022

PamGene Gains CE-IVD Registration for Immunotherapy Guidance Tests

Jul 18, 2022

Immunocore Raises $140M PIPE Financing

Jul 11, 2022

Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways

Jul 6, 2022

Turnstone, Moffitt Cancer Center Get FDA Permission to Study TIL Therapy in Melanoma Patients

Jun 23, 2022

MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium

Jun 8, 2022

Immunocore Racks Up Kimmtrak Approvals in Uveal Melanoma in UK, Australia, Canada

Jun 2, 2022

OnKure Begins Phase Ib/II Trial of HDAC Inhibitor, Pfizer's Mektovi in NRAS-Mutated Melanoma

Jun 2, 2022

InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
Premium

Jun 1, 2022

Iovance Biotherapeutics Shares New TIL Data in Melanoma, Projects Lifileucel FDA Filing in August
Premium

May 26, 2022

Mass General Hospital Gets Funding to Sequence Rare Melanoma Subtypes, Hunt for Novel Drug Targets
Premium

May 16, 2022

Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada

May 10, 2022

OncoHost Raises $35M in Series C Financing

Apr 29, 2022

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

Apr 11, 2022

As NCI-MATCH Winds Down, Cancer Research Community Takes Stock of Lessons Learned
Premium

Apr 6, 2022

Iovance Biotherapeutics Receives Positive FDA Feedback Supporting Lifileucel BLA Submission